首页 > 最新文献

Journal of stem cell and transplantation biology最新文献

英文 中文
Xeno-Transplantation of macro-encapsulated islets and Pluripotent Stem Cell-Derived Pancreatic Progenitors without Immunosuppression. 无免疫抑制的大包膜胰岛和多能干细胞衍生胰腺祖细胞异种移植。
Pub Date : 2017-05-29 DOI: 10.19104/JORM.2017.109
M. A. Bukys, Brandon Bakos, Solomon Afelik, Baruch Zimmerman, B. Barbaro, D. Lin, P. Vaca, T. Goldman, A. Rotem, M. Damaser, J. Oberholzer, U. Barkai, J. Jensen
Islet transplantation effectively treats diabetes but relies on immune suppression and is practically limited by the number of cadaveric islets available. An alternative cellular source is insulin-producing cells derived from pluripotent cell sources. Three animal cohorts were used in the current study to evaluate whether an oxygen-providing macro-encapsulation device, 'βAIR', could function in conjunction with human embryonic stem cells (hESCs) and their derivatives. The first cohort received macro-encapsulated undifferentiated hESCs, a second cohort received hESCs differentiated to a pancreatic progenitor state with limited endocrine differentiation. A reference cohort received human islets. Macro-encapsulation devices were implanted subcutaneously and monitored for up to 4 months. Undifferentiated pluripotent stem cells did not form teratoma but underwent cell death following implantation. Human C-peptide (hC- peptide) was detectable in host serum one week after implantation for both other cohorts. hC-peptide levels decreasing over time but remained detectable up to the end of the study. Key factors associated with mature endocrine cells were observed in grafts recovered from cohorts containing islets and hESC-derivatives including C-peptide, insulin, glucagon and urocortin 3. We conclude that the 'βAIR' macroencapsulation device is compatible with both human islets and pluripotent derivatives, but has a limited capability of sustaining undifferentiated pluripotent cells.
胰岛移植能有效治疗糖尿病,但依赖于免疫抑制,而且实际上受到可用的尸体胰岛数量的限制。另一种细胞来源是来自多能细胞来源的产生胰岛素的细胞。目前的研究使用了三个动物队列来评估一种供氧大胶囊装置“βAIR”是否可以与人类胚胎干细胞(hESCs)及其衍生物一起发挥作用。第一组接受大包封未分化hESCs,第二组接受分化为胰腺祖细胞状态且内分泌分化有限的hESCs。一组参照组接受人胰岛移植。大胶囊装置皮下植入并监测长达4个月。未分化的多能干细胞未形成畸胎瘤,但在植入后发生细胞死亡。另外两组在植入后一周在宿主血清中检测到人c肽(hC肽)。hc -肽水平随着时间的推移而下降,但直到研究结束时仍可检测到。在含有胰岛和hesc衍生物(包括c肽、胰岛素、胰高血糖素和尿皮质素3)的队列中,观察到与成熟内分泌细胞相关的关键因素。我们得出结论,“βAIR”大胶囊装置与人类胰岛和多能性衍生物兼容,但维持未分化多能性细胞的能力有限。
{"title":"Xeno-Transplantation of macro-encapsulated islets and Pluripotent Stem Cell-Derived Pancreatic Progenitors without Immunosuppression.","authors":"M. A. Bukys, Brandon Bakos, Solomon Afelik, Baruch Zimmerman, B. Barbaro, D. Lin, P. Vaca, T. Goldman, A. Rotem, M. Damaser, J. Oberholzer, U. Barkai, J. Jensen","doi":"10.19104/JORM.2017.109","DOIUrl":"https://doi.org/10.19104/JORM.2017.109","url":null,"abstract":"Islet transplantation effectively treats diabetes but relies on immune suppression and is practically limited by the number of cadaveric islets available. An alternative cellular source is insulin-producing cells derived from pluripotent cell sources. Three animal cohorts were used in the current study to evaluate whether an oxygen-providing macro-encapsulation device, 'βAIR', could function in conjunction with human embryonic stem cells (hESCs) and their derivatives. The first cohort received macro-encapsulated undifferentiated hESCs, a second cohort received hESCs differentiated to a pancreatic progenitor state with limited endocrine differentiation. A reference cohort received human islets. Macro-encapsulation devices were implanted subcutaneously and monitored for up to 4 months. Undifferentiated pluripotent stem cells did not form teratoma but underwent cell death following implantation. Human C-peptide (hC- peptide) was detectable in host serum one week after implantation for both other cohorts. hC-peptide levels decreasing over time but remained detectable up to the end of the study. Key factors associated with mature endocrine cells were observed in grafts recovered from cohorts containing islets and hESC-derivatives including C-peptide, insulin, glucagon and urocortin 3. We conclude that the 'βAIR' macroencapsulation device is compatible with both human islets and pluripotent derivatives, but has a limited capability of sustaining undifferentiated pluripotent cells.","PeriodicalId":91131,"journal":{"name":"Journal of stem cell and transplantation biology","volume":"122 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88256348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
A Young Patient with Refractory Multiple Myeloma and Dialysis-Dependent Renal Failure has been Cured by Non-Cryopreserved Autologous Stem Cell Transplantation Followed by Live-Related Kidney Transplantation 一名年轻的难治性多发性骨髓瘤和透析依赖性肾衰竭患者通过非冷冻保存的自体干细胞移植和活体肾移植治愈
Pub Date : 2017-01-01 DOI: 10.21767/2575-7725.100013
K. Al-Anazi, J. Bacal, Nihad Mokhtar, Mohammed Kawari, H. Alhashmi, O. Abduljalil, E. Alshaibani, P. Kalogiannidis, A. Estanislao, A. AlJatham, AlBahrani At, K. Akkari
Management of patients with multiple myeloma having dialysis-dependent renal failure, particularly if the disease is refractory to several lines of therapy, is a difficult task. Cure of such patients represents a real challenge to the treating team. In late November 2009, the diagnosis of multiple myeloma was made in a young patient who had been receiving regular hemodialysis for end-stage renal disease. His myeloma was refractory to four lines of therapy and it responded partially to the fifth line of treatment. Thereafter, the patient received a noncryopreserved autologous hematopoietic stem cell transplantation which brought his myeloma under more optimal control. One year later, he received live-related kidney transplantation. During his subsequent follow-up for fifty four months post-renal transplantation at King Fahad Specialist Hospital in Dammam, Saudi Arabia, no complication has been encountered. As the case is complicated, the literature review will be detailed in order to discuss the various aspects related to care of the patient presented.
多发性骨髓瘤合并透析依赖性肾功能衰竭的患者的管理是一项艰巨的任务,特别是如果该疾病对几种治疗方法都是难治性的。治愈这样的病人对治疗团队来说是一个真正的挑战。2009年11月下旬,一位因终末期肾病而接受定期血液透析的年轻患者被诊断为多发性骨髓瘤。他的骨髓瘤对四种疗法难治性,对第五种疗法有部分反应。此后,患者接受了非冷冻保存的自体造血干细胞移植,使其骨髓瘤得到更优化的控制。一年后,他接受了活体肾移植。肾移植后在沙特阿拉伯达曼法赫德国王专科医院随访54个月,未发生并发症。由于案件是复杂的,文献综述将详细,以讨论有关护理的各个方面提出的病人。
{"title":"A Young Patient with Refractory Multiple Myeloma and Dialysis-Dependent Renal Failure has been Cured by Non-Cryopreserved Autologous Stem Cell Transplantation Followed by Live-Related Kidney Transplantation","authors":"K. Al-Anazi, J. Bacal, Nihad Mokhtar, Mohammed Kawari, H. Alhashmi, O. Abduljalil, E. Alshaibani, P. Kalogiannidis, A. Estanislao, A. AlJatham, AlBahrani At, K. Akkari","doi":"10.21767/2575-7725.100013","DOIUrl":"https://doi.org/10.21767/2575-7725.100013","url":null,"abstract":"Management of patients with multiple myeloma having dialysis-dependent renal failure, particularly if the disease is refractory to several lines of therapy, is a difficult task. Cure of such patients represents a real challenge to the treating team. In late November 2009, the diagnosis of multiple myeloma was made in a young patient who had been receiving regular hemodialysis for end-stage renal disease. His myeloma was refractory to four lines of therapy and it responded partially to the fifth line of treatment. Thereafter, the patient received a noncryopreserved autologous hematopoietic stem cell transplantation which brought his myeloma under more optimal control. One year later, he received live-related kidney transplantation. During his subsequent follow-up for fifty four months post-renal transplantation at King Fahad Specialist Hospital in Dammam, Saudi Arabia, no complication has been encountered. As the case is complicated, the literature review will be detailed in order to discuss the various aspects related to care of the patient presented.","PeriodicalId":91131,"journal":{"name":"Journal of stem cell and transplantation biology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88311802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
It's Getting Hot in Here: Targeting Cancer Stem-like Cells with Hyperthermia. 这里越来越热:用高温疗法靶向癌症干细胞。
Pub Date : 2017-01-01 Epub Date: 2017-12-29
Haidong Huang, Kevin Yu, Alireza Mohammadi, Efstathios Karanthanasis, Andrew Godley, Jennifer S Yu

Cancer stem-like cells (CSCs) are a subset of cancer cells that are resistant to conventional radiotherapy and chemotherapy. As such, CSCs have been recognized as playing a large role in tumor initiation and recurrence. Although hyperthermia is broadly used in cancer treatment either alone or in combination with radio- or chemo-therapy, its potential to target CSCs is not well understood. In this review, we discuss different types of hyperthermia and potential mechanisms of action in cancer treatment, particularly in regards to killing CSCs.

癌症干细胞样细胞(Cancer stem-样cells, CSCs)是对常规放疗和化疗具有耐药性的癌细胞的一个子集。因此,CSCs已被认为在肿瘤的发生和复发中起着重要作用。尽管热疗在癌症治疗中被广泛使用,无论是单独使用还是与放疗或化疗联合使用,但其靶向CSCs的潜力尚不清楚。在这篇综述中,我们讨论了不同类型的热疗及其在癌症治疗中的潜在作用机制,特别是在杀死csc方面。
{"title":"It's Getting Hot in Here: Targeting Cancer Stem-like Cells with Hyperthermia.","authors":"Haidong Huang,&nbsp;Kevin Yu,&nbsp;Alireza Mohammadi,&nbsp;Efstathios Karanthanasis,&nbsp;Andrew Godley,&nbsp;Jennifer S Yu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cancer stem-like cells (CSCs) are a subset of cancer cells that are resistant to conventional radiotherapy and chemotherapy. As such, CSCs have been recognized as playing a large role in tumor initiation and recurrence. Although hyperthermia is broadly used in cancer treatment either alone or in combination with radio- or chemo-therapy, its potential to target CSCs is not well understood. In this review, we discuss different types of hyperthermia and potential mechanisms of action in cancer treatment, particularly in regards to killing CSCs.</p>","PeriodicalId":91131,"journal":{"name":"Journal of stem cell and transplantation biology","volume":"2 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/68/nihms938338.PMC6287629.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36764801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Homeodomain Transcription Factor Msx-2 Regulates Uterine Progenitor Cell Response to Diethylstilbestrol. 同源结构域转录因子Msx-2调控子宫祖细胞对己烯雌酚的应答。
Pub Date : 2015-01-01 Epub Date: 2015-05-12 DOI: 10.19104/jstb.2015.105
Yan Yin, Congxing Lin, Ivy Zhang, Alexander V Fisher, Maulik Dhandha, Liang Ma

The fate of mouse uterine epithelial progenitor cells is determined between postnatal days 5 to 7. Around this critical time window, exposure to an endocrine disruptor, diethylstilbestrol (DES), can profoundly alter uterine cytodifferentiation. We have shown previously that a homeo domain transcription factor MSX-2 plays an important role in DES-responsiveness in the female reproductive tract (FRT). Mutant FRTs exhibited a much more severe phenotype when treated with DES, accompanied by gene expression changes that are dependent on Msx2. To better understand the role that MSX-2 plays in uterine response to DES, we performed global gene expression profiling experiment in mice lacking Msx2 By comparing this result to our previously published microarray data performed on wild-type mice, we extracted common and differentially regulated genes in the two genotypes. In so doing, we identified potential downstream targets of MSX-2, as well as genes whose regulation by DES is modulated through MSX-2. Discovery of these genes will lead to a better understanding of how DES, and possibly other endocrine disruptors, affects reproductive organ development.

小鼠子宫上皮祖细胞的命运在出生后5 - 7天确定。在这个关键的时间窗口,暴露于内分泌干扰物己烯雌酚(DES)可以深刻地改变子宫细胞分化。我们之前已经证明同源结构域转录因子MSX-2在女性生殖道(FRT)的des反应性中起重要作用。突变型FRTs在用DES治疗时表现出更严重的表型,并伴有依赖于Msx2的基因表达变化。为了更好地了解MSX-2在子宫对DES反应中的作用,我们在缺乏Msx2的小鼠中进行了全球基因表达谱实验,并将这一结果与我们之前发表的野生型小鼠的微阵列数据进行了比较,我们提取了两种基因型中的共同和差异调控基因。通过这样做,我们确定了MSX-2的潜在下游靶点,以及DES通过MSX-2调节的基因。这些基因的发现将有助于更好地理解DES以及其他内分泌干扰物是如何影响生殖器官发育的。
{"title":"Homeodomain Transcription Factor Msx-2 Regulates Uterine Progenitor Cell Response to Diethylstilbestrol.","authors":"Yan Yin,&nbsp;Congxing Lin,&nbsp;Ivy Zhang,&nbsp;Alexander V Fisher,&nbsp;Maulik Dhandha,&nbsp;Liang Ma","doi":"10.19104/jstb.2015.105","DOIUrl":"https://doi.org/10.19104/jstb.2015.105","url":null,"abstract":"<p><p>The fate of mouse uterine epithelial progenitor cells is determined between postnatal days 5 to 7. Around this critical time window, exposure to an endocrine disruptor, diethylstilbestrol (DES), can profoundly alter uterine cytodifferentiation. We have shown previously that a homeo domain transcription factor MSX-2 plays an important role in DES-responsiveness in the female reproductive tract (FRT). Mutant FRTs exhibited a much more severe phenotype when treated with DES, accompanied by gene expression changes that are dependent on <i>Msx2</i>. To better understand the role that MSX-2 plays in uterine response to DES, we performed global gene expression profiling experiment in mice lacking <i>Msx2</i> By comparing this result to our previously published microarray data performed on wild-type mice, we extracted common and differentially regulated genes in the two genotypes. In so doing, we identified potential downstream targets of MSX-2, as well as genes whose regulation by DES is modulated through MSX-2. Discovery of these genes will lead to a better understanding of how DES, and possibly other endocrine disruptors, affects reproductive organ development.</p>","PeriodicalId":91131,"journal":{"name":"Journal of stem cell and transplantation biology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596533/pdf/nihms-723300.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34248175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Heart Regeneration with Embryonic Cardiac Progenitor Cells and Cardiac Tissue Engineering. 胚胎心脏祖细胞与心脏组织工程的心脏再生。
Pub Date : 2015-01-01 DOI: 10.19104/JSTB.2015.104
Shuo Tian, Qihai Liu, Leonid Gnatovskiy, P. Ma, Zhong Wang
Myocardial infarction (MI) is the leading cause of death worldwide. Recent advances in stem cell research hold great potential for heart tissue regeneration through stem cell-based therapy. While multiple cell types have been transplanted into MI heart in preclinical studies or clinical trials, reduction of scar tissue and restoration of cardiac function have been modest. Several challenges hamper the development and application of stem cell-based therapy for heart regeneration. Application of cardiac progenitor cells (CPCs) and cardiac tissue engineering for cell therapy has shown great promise to repair damaged heart tissue. This review presents an overview of the current applications of embryonic CPCs and the development of cardiac tissue engineering in regeneration of functional cardiac tissue and reduction of side effects for heart regeneration. We aim to highlight the benefits of the cell therapy by application of CPCs and cardiac tissue engineering during heart regeneration.
心肌梗死(MI)是世界范围内导致死亡的主要原因。干细胞研究的最新进展为通过干细胞为基础的治疗实现心脏组织再生提供了巨大的潜力。虽然在临床前研究或临床试验中已将多种细胞类型移植到心肌梗死心脏,但瘢痕组织的减少和心功能的恢复一直不大。一些挑战阻碍了干细胞治疗心脏再生的发展和应用。应用心脏祖细胞(CPCs)和心脏组织工程进行细胞治疗在修复受损心脏组织方面显示出巨大的前景。本文综述了胚胎心肌干细胞的应用现状,以及心脏组织工程在心脏功能组织再生和减少心脏再生副作用方面的研究进展。我们的目的是强调在心脏再生中应用细胞疗法和心脏组织工程的益处。
{"title":"Heart Regeneration with Embryonic Cardiac Progenitor Cells and Cardiac Tissue Engineering.","authors":"Shuo Tian, Qihai Liu, Leonid Gnatovskiy, P. Ma, Zhong Wang","doi":"10.19104/JSTB.2015.104","DOIUrl":"https://doi.org/10.19104/JSTB.2015.104","url":null,"abstract":"Myocardial infarction (MI) is the leading cause of death worldwide. Recent advances in stem cell research hold great potential for heart tissue regeneration through stem cell-based therapy. While multiple cell types have been transplanted into MI heart in preclinical studies or clinical trials, reduction of scar tissue and restoration of cardiac function have been modest. Several challenges hamper the development and application of stem cell-based therapy for heart regeneration. Application of cardiac progenitor cells (CPCs) and cardiac tissue engineering for cell therapy has shown great promise to repair damaged heart tissue. This review presents an overview of the current applications of embryonic CPCs and the development of cardiac tissue engineering in regeneration of functional cardiac tissue and reduction of side effects for heart regeneration. We aim to highlight the benefits of the cell therapy by application of CPCs and cardiac tissue engineering during heart regeneration.","PeriodicalId":91131,"journal":{"name":"Journal of stem cell and transplantation biology","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76325614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
期刊
Journal of stem cell and transplantation biology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1